Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239677 | PMC |
| http://dx.doi.org/10.1111/ene.14813 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation.
Front Neurol
November 2024
Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Background: The prevalence of patients positive for muscle-specific kinase antibody (hereafter, MuSK-Ab) accounts for 5-8% of all myasthenia gravis (MG) cases. Currently, efgartigimod has shown good therapeutic effects in MUSK-Ab-positive MG patients in a phase III clinical trial. However, phase III clinical trials tend to exclude MG patients in exacerbation, and there are only few real-world studies on the efficacy of efgartigimod in MuSK-Ab-positive myasthenic crisis (MC) patients.
View Article and Find Full Text PDFEfgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series.
Front Immunol
August 2024
Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Article Synopsis
- Efgartigimod has shown effectiveness and safety in treating myasthenic crisis (MC) patients, leading to successful ventilation weaning.
- The study involved 10 patients, assessing their improvement through the MG-ADL scale and measuring immune markers before and after treatment.
- Results indicated significant reductions in MG-ADL scores and corticosteroid dosages, along with changes in specific T cell populations following efgartigimod therapy.
Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis.
Ir J Med Sci
December 2024
Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Background: Increasing data are available on the use and efficacy of rituximab (RTX) in patients with anti-muscle-specific tyrosine kinase (MuSK)-positive myasthenia gravis (MG), especially those steroid-dependent or unresponsive to traditional immunotherapies.
Aims: We aimed to evaluate the clinical characteristics and treatment responses of adult patients with generalized anti-MuSK-positive MG treated with RTX.
Methods: We retrospectively recruited 16 patients who were on RTX, between January 2010 and September 2023.
Myasthenia gravis Lambert-Eaton overlap syndrome: Recommended modification for the diagnostic criteria.
Muscle Nerve
October 2024
Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Article Synopsis
- In 2016, the term MLOS (myasthenia gravis Lambert-Eaton overlap syndrome) was introduced to describe a condition that combines features of both myasthenia gravis and Lambert-Eaton myasthenic syndrome.
- A total of 55 patients with MLOS have been identified to help understand this overlap syndrome better.
- The study suggests updating the diagnostic criteria for myasthenia gravis to include testing for MuSK positive antibodies, which helped identify two MLOS patients under these new guidelines.
An unusual initiation of an ocular form of MuSK-positive myasthenia gravis after magnesium administration: a rare case report.
Ann Med Surg (Lond)
July 2024
Department of Neurology, Alwatani Hospital, Hama.
Introduction And Importance: The primary clinical symptom in people with myasthenia gravis (MG) is muscle weakness that gets worse with activity and gets better with rest; often, the first symptoms are ocular ones, such as ptosis and double vision. On the other hand, individuals with anti-muscle-specific tyrosine kinase may present with unusual symptoms. Nonetheless, it is hypothesized that muscle-specific tyrosine kinase antibodies may be present when no antibodies are present, along with bulbar and respiratory symptoms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!